| Title |
Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
|
|---|---|
| Published in |
Journal of Neuro-Oncology, December 2017
|
| DOI | 10.1007/s11060-017-2702-7 |
| Pubmed ID | |
| Authors |
M. J. Lobon-Iglesias, G. Giraud, D. Castel, C. Philippe, M. A. Debily, C. Briandet, F. Fouyssac, E. de Carli, C. Dufour, D. Valteau-Couanet, C. Sainte-Rose, T. Blauwblomme, K. Beccaria, M. Zerah, S. Puget, R. Calmon, N. Boddaert, S. Bolle, P. Varlet, J. Grill |
| Abstract |
Children with diffuse intrinsic pontine glioma (DIPG) need new and more efficient treatments. They can be developed at relapse or at diagnosis, but therefore they must be combined with radiotherapy. Survival of children after recurrence and its predictors were studied to inform the possibility to design early phase clinical trials for DIPG at this stage. Among 142 DIPG patients treated between 1998 and 2014, 114 had biopsy-proven DIPG with histone H3 status available for 83. We defined as long survivors' patients who survived more than 3 months after relapse which corresponds to the minimal life expectancy requested for phase I/II trials. Factors influencing post-relapse survival were accordingly compared between short and long-term survivors after relapse. Fifty-seven percent of patients were considered long survivors and 70% of them had a Lansky Play Scale (LPS) above 50% at relapse. Patients who became steroids-independent after initial treatment for at least 2 months had better survival after relapse (3.7 versus 2.6 months, p = 0.001). LPS above 50% at relapse was correlated with better survival after relapse (3.8 versus 1.8 months, p < 0.001). Patients with H3.1 mutation survived longer after relapse (4.9 versus 2.7 months, p = 0.007). Patients who received a second radiotherapy at the time of relapse had an improved survival (7.5 versus 4 months, p = 0.001). In the two-way ANOVA analysis, steroid-independence and LPS predicted survival best and the type of histone H3 (H3.1 or H3.3) mutated did not improve prediction. Survival of many DIPG patients after relapse over 3 months would make possible to propose specific trials for this condition. Steroid-independence, H3 mutation status and LPS should be considered to predict eligibility. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 58 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 17% |
| Other | 6 | 10% |
| Student > Doctoral Student | 6 | 10% |
| Student > Ph. D. Student | 5 | 9% |
| Student > Bachelor | 3 | 5% |
| Other | 13 | 22% |
| Unknown | 15 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 38% |
| Neuroscience | 7 | 12% |
| Biochemistry, Genetics and Molecular Biology | 6 | 10% |
| Agricultural and Biological Sciences | 2 | 3% |
| Sports and Recreations | 1 | 2% |
| Other | 3 | 5% |
| Unknown | 17 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2019.
All research outputs
#18,584,192
of 23,018,998 outputs
Outputs from Journal of Neuro-Oncology
#2,263
of 2,987 outputs
Outputs of similar age
#325,946
of 438,155 outputs
Outputs of similar age from Journal of Neuro-Oncology
#60
of 104 outputs
Altmetric has tracked 23,018,998 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,987 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 438,155 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 104 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.